A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
Professor Chan Cheah
TG Therapeutics, Inc
1
B-Cell Lymphoma
Patients with relapsed or refractory B-Cell Lymphoma will receive weekly infusions of TG-1801 for the first 2 cycles (2 months) and then monthly infusions, for a total of 6 months maximum treatment
Include, but not limited to, the following:
Inclusion criteria:
- Patients must be 18 years or over
- Relapsed or refractory B-Cell Lymphoma
- Measurable disease and adequate organ function (as specified in the protocol)
- No other active cancers
- No other major health problems
Exclusion Criteria:
- Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day
- Prior autologous stem cell transplant within 6 months
- Active Hepatitis B or Hepatitis C
TG-1801-101
NCT03804996